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Abstract
This study investigated the efficacy and safety 
of an imidacloprid 10 %/moxidectin 2.5 % spot-on 
combination (Advocate®, Advantage® Multi, Bayer) 
against immature and mature stages of Spirocerca 
lupi in experimentally infected dogs. 24 dogs were 
allocated to 3 groups and infected with approxi-
mately 10 L3 larvae of S. lupi orally on study day 
(SD) +2, +14, +28 and +42. Group 1 remained as 
untreated control group. Group 2 dogs were treated 
on SD –28, 0, and thereafter monthly until Day 280 
(12 treatments). Group 3 dogs were treated weekly 
on 19 occasions starting on SD +170. The dosage for 
all treatments was the licensed dose of 10–25 mg 
imidacloprid/2.5–6.25 mg moxidectin per kg body 
weight. All dogs were examined on SD +169 or 
+176 by endoscopy. Group 3 dogs were additionally 
examined approximately every two weeks up to 
Day 296. On Day +308 or +310, all dogs were nec-
ropsied to recover S. lupi worms and to quantify 
lesions in the thoracic aorta and oesophagus. Dogs 
in the control group were adequately infected with 
S. lupi, demonstrated by the extensive damage to 
the thoracic aorta, the nodules in the oesophagus 
and the large numbers of worms recovered. In 
total 144 worms were collected (geometric mean of 
16.8 worms per dog). Dogs in group 2 had no or very 
slight damage to the thoracic aorta and no nod-
ules or worms in the oesophagus, indicating 100 % 
efficacy of the monthly treatments. Dogs in group 
3 were also adequately infected, showing nodules 
in the oesophagus before initiation of weekly treat-
ment, and at necropsy extensive damage was seen 
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in the thoracic aorta. After treatment, three dogs of 
8 still had a few nodules and in total three worms 
(GM of 0.25 per dog) were recovered, demonstrat-
ing an efficacy of 98.5 % against adult S. lupi. All 
dogs tolerated the treatment well and no treat-
ment-related adverse events occurred.
Introduction
Spirocerca lupi is a spirurid nematode parasite, 
the adults of which are usually found in fibrous 
nodules in the wall of the oesophagus of dogs and 
other canids, although cats and other wild felids 
may sometimes also act as final hosts (Bailey 1972; 
Taylor et al. 2007). In general, large breed dogs 
appear to be most at risk of infection, especially 
hunting dogs, and Labrador retrievers appear to be 
more susceptible than other breeds (Mazaki-Tovi 
et al. 2002; Mylonakis et al. 2001), but this may 
be linked to specific lifestyles providing greater 
or lesser exposure to the parasite (van der Merwe 
et al. 2008). There is no age or sex predilection, 
although animals under six months of age, even 
if infected, will not show clinical signs of infection 
because oesophageal spirocercosis develops gradu-
ally as the worms mature over an approximately 
six months period (van der Merwe et al. 2008).
Although S. lupi appears to have a worldwide dis-
tribution (Lavy et al. 2003), it occurs most often in 
warmer tropical and subtropical climates (Bailey 
1972; Berry 2000; van der Merwe et al. 2008). The 
widespread importance of this parasite is demon-
strated by numerous prevalence studies conducted 
in a number of countries over the last 5 decades 
(Brodey et al. 1977; du Toit et al. 2008; Haralabidis 
et al. 1988; Lobetti 2000; Murray 1968; Mylonakis 
et al. 2001; Oliveira-Sequeira et al. 2002; Pandey 
et al. 1987; Pence and Stone 1978; Ramírez-Barrios 
et al. 2004).
Fig. 1a  SEM of the anterior end of an adult Spirocerca lupi showing the hexagonal mouth, cephalic papillae  (arrows) 
and cervical papilla (arrow head)
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The distribution of the parasite is dependent on 
the occurrence of the intermediate hosts, which 
include coprophagous beetles of the family Scara-
baeidae (Bailey et al. 1963). Paratenic or transport 
hosts can also serve as sources of infection for the 
final host if ingested and infection may be trans-
ferred from one paratenic host to another via pre-
dation (Fox et al. 1988). Lizards, chickens, mice 
and a number of insectivorous vertebrates may act 
as paratenic hosts for the infective larvae (Bailey 
1972; Bowman 2009; Taylor et al. 2007).
The ability of this parasite to utilise vertebrate 
paratenic hosts increases the availability of infec-
tive stages due to an increased number of potential 
intermediate hosts, as well as the relatively longer 
lifespans of such paratenic hosts. Similar roles of 
additional paratenic hosts are also reported for 
other parasites such as Angiostrongylus vasorum, 
where frogs prey on the intermediate host snail and 
widen the scope of prey for the final canid host. 
(Bolt et al. 1993)
After the intermediate respectively paratenic host 
is ingested, the encysted third-stage larvae (L3) 
excyst in the stomach before migrating through the 
mucosa. The larvae then migrate within the walls of 
the gastric and gastroepiploic arteries to the aorta 
and then cranially into the thoracic aorta; this por-
tion of the migration usually taking approximately 
10 days (Bailey 1972; van der Merwe et al. 2008). 
Here the larvae will remain for up to three months, 
undergoing two further moults to emerge as young 
adults, subsequently migrating directly into the 
caudal oesophageal wall, penetrating the mucosa 
before returning to and settling in the submucosa 
or adventitia to complete their maturation and life 
cycle (Bailey 1972; van der Merwe et al. 2008).
Adult worms (Figs. 1a and 1b) are spiralled and 
pink to blood red in colour, the males growing up 
to 55 mm and the females up to 80 mm in length 
(Soulsby 1982; Taylor et al. 2007). The females pass 
eggs (Fig. 1c) through the perforation in the muco-
sa, where they can be passed out of the body by 
vomiting or by swallowing and subsequent defaeca-
tion; subsequent ingestion of the eggs by copropha-
gous beetles starts the life cycle again (Fig. 2).
The pathological changes associated with S. lupi 
infections are brought about by the migration of the 
larvae through the various tissues and organs as 
well as their persistent presence in the body (Berry 
2000; Gal et al. 2005). The most significant lesions 
include aortic aneurysms, posterior thoracic spon-
dylitis and oesophageal nodule formation which 
often progresses to metastatic sarcoma (Bailey 
1963; Dvir et al. 2010).
The migration of the larvae within the walls of 
blood vessels results in haemorrhage, necrosis and 
the exudation of neutrophils locally (van der Merwe 
et al. 2008). The above-mentioned lesions usually 
Fig. 1c  Spirocerca lupi eggs as found during flotation 
procedure. Bar: 40 μm
Fig. 1b  Spirocerca lupi adult specimen collected from 
one dog post mortem following rupture of the 
aorta (dog not part of the study population)
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heal completely, except in the thoracic aorta where 
migrating larvae damage the elastic and muscle 
layers, causing subsequent degeneration, fibrosis, 
calcification and ossification (Bailey 1963; Bailey 
1972; van der Merwe et al. 2008). These processes 
culminate in scarring of the intima and varying 
degrees of aortic aneurysm formation (Johnson 
1992). The aortic aneurysms, considered pathog-
nomonic for S. lupi infections, are frequently the 
cause for acute death due to aortic rupture and 
fatal haemorrhage (Bailey 1963, 1972).
Subclinical infections aside, antemortal clinical 
signs in dogs infected with Spirocerca are varied 
and may include coughing, regurgitation, anorexia, 
weight loss, vomiting, dysphagia, salivation, inhala-
tion pneumonia, paraparesis, back pain, melaena, 
anaemia and central nervous system involvement 
(Dvir et al. 2001; Du Plessis et al. 2007; van der 
Merwe et al. 2008). A diagnosis of spirocercosis in 
the dog may be aided by the presence of various 
combinations of the above-mentioned symptoms as 
well as the presence of S. lupi eggs in the stool, dem-
onstrated by a modified faecal flotation technique 
(Markovics and Medinski 1996), reported to increase 
the diagnostic sensitivity of the test. Various radio-
graphic changes such as a caudal oesophageal mass 
with accompanying thoracic vertebral periosteal 
reactions are also supportive of a diagnosis (Dvir 
et al. 2001), but direct visualisation of oesopha-
geal nodules or neoplastic masses by means of an 
endoscopic examination remains the most sensitive 
method of diagnosis (van der Merwe et al. 2008).
Fig. 2  Schematic representation of the life cycle of Spirocerca lupi
Spirocerca lupin life cycle
 L3 larvae emerge from dung 
beetle in the stomach, penetrate 
the stomach wall and migrate to 
the gastric arteries. Larvae then 
travel upstream to the aorta.
 The L3 larvae may spend up 
to 3 month inside nodules in the 
wall of the aorta. Here the L4 
larval stage and fi nally emerge 
from the nodules as young 
adults. The process results in an-
eurism formation within the 
aortic wall, which may rupture at 
any time leading to acute death.
 Migration through the aorta and 
into the wall of the oesophagus
occurs, where more nodules, each 
containing several adult worms, are 
formed. Adults emerge from a small 
opening to lay eggs into the oeso-
phagus. Nodules may impede swal-
lowing and often become cancerous.
 Eggs are swallowed, passed out in the 
faeces and are ingested by dung beetles 
whilst feeding. Larvae hatch from the eggs 
and encyst inside the dung beetle. Beetles 
may be directly ingested or ingested with 
faces by coprophagous dogs. Paratenic 
may become infected by feeding on dung 
beetles. Dogs may then become infested 









Intermediate host: Dung beetle 




Up until the time of this study, the most effective 
treatment for non-neoplastic spirocercosis appeared 
to be doramectin, administered subcutaneously in 
varying regimens (Berry 2000; Lavy et al. 2002; 
van der Merwe et al. 2008), although concerns exist 
about its extra-label use, mode of administration 
and breed-specific toxicity (Kok et al. 2010). Oral-
ly administered milbemycin oxime has also been 
shown to have some efficacy against Spirocerca lupi 
(Kelly et al. 2008; Kok et al. 2010, 2011).
The prevalence of Spirocerca lupi in many parts of 
the world is ever increasing (Kok et al. 2010) and 
the need exists for a licensed, cost-effective prod-
uct which will provide adequate preventative and 
therapeutic efficacy, demonstrating effectiveness 
against the migrating immature stages as well as 
the encapsulated adult stages of the parasite. A 
study conducted on Réunion Island has indicated 
that a topically applied formulation consisting of 
imidacloprid 10 % / moxidectin 2.5 % can be safely 
and successfully used to prevent canine spirocer-
cosis in puppies (Le Sueur et al. 2010), but the 
preventative and therapeutic ability of this formu-
lation needed to be further investigated. A study 
was therefore designed to investigate the preven-
tive efficacy (efficacy against immature stages), 
the therapeutic efficacy (efficacy against mature 
stages) and the safety of an imidacloprid 10 %/
moxidectin 2.5 % spot-on formulation (Advocate®, 
Advantage® Multi, Bayer) against Spirocerca lupi 
in experimentally infected dogs.
Materials and methods
The study took the form of a monocentric, ran-
domised, parallel-arm, partially blinded, negative 
controlled, terminal efficacy study and was con-
ducted on the premises of Clinvet International, 
a contract research organisation located in Bloem-
fontein, South Africa. The study was conducted 
in compliance with the International Cooperation 
on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products 
(VICH) Guideline (GL) 9 on Good Clinical Practice. 
A total of 24 purpose-bred, mixed breed dogs 
between the ages of 7 and 14 months were used. 
All animals weighed between 11 kg and 22 kg and 
were determined to be healthy and free of para-
sites by veterinary personnel at the start of the 
study. All were treated with a suitable anthelmin-
tic, not from the macrocyclic lactone family, at least 
14 days before the onset of group allocation on Day 
–29. Each animal was identified by means of an 
implanted electronic transponder.
The South African animal welfare regulations, 
detailed in the South African National Standard 
“SANS 10386:2008 The care and use of animals for 
scientific purposes”, were strictly adhered to and 
the study protocols were submitted to the Clinvet 
Animal Ethics Committee for approval. The com-
position of this committee was in compliance with 
the above-mentioned national standard.
Study design
The study was conducted in three phases in order 
to keep the infection episodes adequately spaced, so 
that the number of infective larvae required at each 
infection episode would not be excessive. The study 
population (n = 24) was divided into 3 study groups 
using randomisation based on gender and body 
weight. After being assigned to a group, the animals 
were then randomly assigned to phase 1, 2 or 3 of 
the study. In phases 1 and 2, each group consisted 
of 3 animals (9 animals in total). In the third phase, 
each group consisted of 2 animals (6 animals in 
total). The layout of the study was the same for all 
phases and all animals were individually housed in 
order to reduce the risk of cross-contamination with 
test product as well as facilitate daily health obser-
vations and collection of stools for faecal egg counts.
All animals were regularly allowed individual 
access to runs in order to exercise and were treat-
ed monthly with an effective acaricide (Advantix®, 
Bayer) for ectoparasite control. Each animal was 
dosed with a suitable oral anthelmintic (not con-
taining a macrocyclic lactone) and vaccinated prior 
to the start of the trial.
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The Investigational Veterinary Product (IVP) 
in this study was Advocate® (Bayer), a topically 
applied endectocide containing imidacloprid 10 %/
moxidectin 2.5 %. The treatment regimen of each 
group is demonstrated in Table 1.
Group 1 served as the negative control group that 
remained untreated. Group 2 received monthly 
treatments with the IVP throughout the study, 
beginning 28 days prior to the first artificial infec-
tion with S. lupi, and was used to determine preven-
tative efficacy. Group 3 received weekly treatments 
with the IVP from 170 days post infection (p.i.), 
subsequent to confirmation of the presence of 
S. lupi nodules in the oesophagus, and treatment 
continued until 2 weeks prior to termination of the 
study. This group was used to determine therapeu-
tic efficacy. Each animal received a minimum of 
10 mg/kg (milligrams per kilogram body weight) 
imidacloprid and 2.5 mg/kg moxidectin with each 
dose of Advocate® that was applied. Table 1 shows 
the dosages applied in accordance with the manu-
facturer’s instructions.
All animals were examined endoscopically on Day 
+169 or +176 to determine whether or not oesoph-
ageal nodules (i.e. oesophageal spirocercosis) had 
already developed; thereafter animals in group 
3 were endoscopically examined approximately 
every 2 weeks and the presence, size and position 
of any nodules present were recorded.
Faecal samples were collected once weekly from 
Day +170 and examined for the presence of S. lupi 
eggs. Table 2 gives a timeline depicting important 
events pertaining to the study.
As treatment regimen and examination proce-
dures (e.g. endoscopy schedules) differed between 
the respective groups, no blinding procedures were 
applied during most of the study. A blinding pro-
cedure was, however, applied during the necropsy 
procedures. Blinding codes were allocated to indi-
vidual animals to ensure that persons performing 
the actual necropsy examinations and assessments 
were unaware of group allocations.
Induced infection of dogs
All animals in the study were challenged with 
approximately 10 infective L3 larvae on Days +2, 
+14, +28 and +42 (+/–2 days) of the study. The infec-
tive larvae were dissected out of naturally infected 
scarabaeid beetles, collected from an area in South 
Africa known to be endemic for spirocercosis. The 
excysted larvae were kept in saline and were dosed 
to the dogs within 24 hours of their recovery.
After being fasted for approximately 12 hours, 
each dog was dosed with the 10 infective larvae, 
suspended in 2 ml (millilitres) of saline, by means 
of a stomach tube. After the saline containing the 
larvae was dosed, the stomach tube was rinsed 
through with a further 10 ml of saline before 
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removal. Each animal was treated with a low dose 
of acetylpromazine maleate approximately 20 min 
before the procedure to provide for a mild degree 
of muscle relaxation combined with an anti-emetic 
effect. The procedure was performed by a veteri-
narian and lasted no longer than 30 seconds in each 
case. During and for at least 1 hour directly after 
infection, the dogs were observed continuously for 
any vomition, which was recorded if present.
In spite of premedication, with acetylpromazine 
maleate all dogs infected with S. lupi larvae vom-
ited after introduction of the larvae, all within the 
first hour with one exception. In most instances, 
the vomit was licked up again by the dog. It was 
known from previous experience that few, if any, 
larvae were ever present in the vomit and that the 
vomiting would have little effect on the potential 
success of establishment of the infections.
Assessment 
Endoscopic examination
Dogs in all groups were examined endoscopically 
under general anaesthetic on Day +169 or +176. 
From Day +183 onwards, only the dogs in group 
3 were endoscopically examined, initially every 
2 weeks but later amended to allow slightly long-
er intervals between examinations; this decision 
was taken because some of the animals started to 
experience delayed recovery times and increased 
extensor rigidity after general anaesthetic, and the 
concern existed that this was due to the high fre-
quency of exposure to general anaesthetic.
Each animal was pre-medicated 10 minutes prior 
to the procedure with intravenous diazepam and 
atropine and induced with intravenous propofol, 
titrated to effect. After intubation and inflation 
of the endotracheal tube cuff, animals were main-
tained on halothane inhalation anaesthesia in left 
lateral recumbence, with the head and neck extend-
ed, whilst the endoscopic examination took place.
The oesophageal mucosa was examined over its 
entire length up to the gastro-oesophageal orifice 
and the number, size and position of any nodules 
or nipple-like protuberances (van der Merwe et al. 
2008) were recorded. Each video endoscopy was 
recorded digitally and a number of still images of 
various lesions were recorded.
Faecal examination
Since animals were individually housed, individual 
faecal sampling was possible and S. lupi egg counts 
were conducted on all animals on a weekly basis 
from Day +170 onwards. A sugar flotation method, 
as described by Marcovics and Medinski (1996), 
was used and counts were expressed as eggs per 
gram of faeces (epg).
Necropsy
Necropsy of the animals in phase 2 took place on 
Day +308 and on Day +310 for phases 1 and 3. 
The animals had food withheld for 16 to 20 hours 
before humane euthanasia using an overdose of 
pentobarbitone, administered intravenously. At 
Table 2 Study schedule
Day Activity
–32 Animal phase starting date
–29 Allocation to groups
–28 1st IVP treatment, group 2
+2 1st infection with 10 S. lupi L3
+42 Last infection with 10 S. lupi L3
+169
+176
First endoscopy, all groups
+170
1st Faecal egg counts 
1st IVP treatment, group 3
+ 280 Last IVP treatment, group 2
+296 Last IVP treatment, group 3
+306–308 Last faecal egg counts
+308/+310




Table 3 Aortic damage score criteria
Score Description
1 No lesions visible on inside
2 Inflammatory/puckered lesions only just visible
3 Two to three lesions clearly visible, no aneurisms
4 Several distinct inflammatory lesions; parasite bore tracks are often visible; aneurisms just start developing
5 Distinctly damaged area of aorta; all of the above evident
6 Worst case scenario: aorta severely damaged over a large area; several aneurisms evident
necropsy, an extensive post-mortem examination of 
the thoracic aorta and oesophagus was conducted 
and all lesions described and quantified as far as 
possible. The size of S. lupi lesions in the oesopha-
gus and their position relative to the diaphragm 
was measured. Photographic documentation was 
also compiled.
All nodules were opened and the contents washed 
through a 0.15-mm sieve. After backwashing, the 
contents of the sieve were macroscopically exam-
ined and all helminths and helminth fragments 
removed and preserved. A blinding procedure, 
which included coding of tissue and organ samples 
removed, was followed to ensure that the persons 
performing the parasite and lesion assessments 
were unaware of group allocations. The number 
of nodules on both oesophagus and thoracic aorta 
were recorded and the diameter of such nodules 
was measured as far as possible. Furthermore, the 
severity of damage to the aorta was scored using 
the criteria laid out in Table 3.
Calculation of efficacy
The main numerical assessment for statistical 
analysis was the number of worms recovered at 
necropsy in the treated groups (groups 2 and 3) 
compared to the control group (group 1). Percent-
age efficacy, as a measure of a treatment effect to 
prevent encapsulation, was the primary endpoint 
for group 2. Percentage efficacy, as a measure of 
a treatment effect against encapsulated adults, 
was the primary endpoint for group 3. Adequacy 
of infection and a significant difference in worm 
counts between the treated and control groups 
were required to claim a treatment effect. Evalu-
ation of the adequacy of infection of the dogs was 
based on parasitological criteria.
The treated groups were also statistically com-
pared to the control group with regard to the reduc-
tion in faecal egg output. The percentage reduction, 
as a measure of treatment effect, was a secondary 
endpoint.
Data on the size and numbers of lesions were used 
mainly descriptively, as were data resulting from 
endoscopic examinations.
The efficacy of treatment with IVP (i.e. either to 
prevent encapsulation of S. lupi or efficacy against 
encapsulated adults) was reflected in the number 
of S. lupi worms recovered at necropsy in the treat-
ed groups compared to the control group.
The formula was:
% Efficacy = (N2 – N1)/N2 × 100
N1 =  Arithmetic Mean (AM) or Geometric Mean 
(GM) of the number of S. lupi recovered at 
necropsy for group 2/group 3
N2 =  AM or GM of the number of S. lupi 
recovered at necropsy for group 1 (control)
For calculations of efficacy, arithmetic and geo-
metric means were used. The efficacy based on 
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geometric means was considered primary. To allow 
for data sets with zero values, all data were trans-
formed to (n + 1), geometric means calculated and 
1 subtracted from the result to obtain a reasonable 
estimate of the geometric mean.
To better fulfil the requirements for normality and 
homogeneity of variance, each individual value 
used in statistical comparisons (e.g. worm num-
bers) was transformed to log (n + 1) for further 
analysis.
For comparison between groups, an analysis of vari-
ance (ANOVA) with a treatment effect was applied 
to the numbers of worms after a logarithmic trans-
formation of the (worm + 1) counts. Statistical sig-
nificance was set at p < 0.05. Statistical analyses 
were conducted using SAS Version 8.02 or higher.
The efficacy of treatment with the IVP to reduce 
faecal egg output in dogs in the treated groups com-
pared to those in the control group was expressed 
as percentage reduction, calculated for each week 
following Day +170.
The formula was:
% Reduction = (E2 – E1)/E2 × 100
E1 =  Arithmetic (AM) or Geometric Mean (GM) of 
the particular week epg value for group 2 or 
group 3
E2 =  AM or GM of the particular week epg value 
for group 1 (control)
The percentage reduction was analysed statisti-




The untreated control dogs in group 1 were exam-
ined only on Day +169 or +176 and not again. All 
dogs in this group had one to six nodules in the 
oesophagus, confirming the success of establish-
ment of S. lupi following experimental infections.
The dogs in group 2, which received monthly treat-
ment with the IVP starting on Day –28, had no 
nodules in the oesophagus on Day +169 or +176. 
These dogs were also not examined endoscopically 
again.
The dogs in group 3 were also examined on Day 
+169 or +176 and regularly thereafter, initially at 
14-day intervals but later with longer intervals as 
discussed earlier. Seven of the eight dogs in group 
3, treated for the first time on Day +170, had one 
to six nodules in the oesophagus on Day +169/+176, 
thus also confirming the success of establishment 
of the S. lupi infections. One dog had no visible 
nodules in the oesophagus and it remained nega-
tive throughout the examination period. In three 
other dogs, the number of nodules remained more 
or less the same (2 to 3) throughout the examina-
tion period. In the four remaining dogs, the number 
of nodules decreased from 4–6 initially to 1 or 2 at 
the end of the examination period. On the last day 
of examination (Day +281 or +295), 1–3 nodules 
were still observed endoscopically in seven of the 
eight dogs.
Faecal egg counts
Figure 3 shows the pattern of change in weekly 
geometric mean (GM) S. lupi epg values for groups 
1 and 3 from Day +170 up to the end of the study.
In the untreated group 1, egg numbers were ini-
tially low and found sporadically, not always in 
the same dogs. From about Day +208 egg numbers 
were larger and eggs were found consistently in 
six of the eight dogs. From about Day +268 egg 
numbers increased and eggs were mostly found in 
all dogs on all occasions. Epg values were mostly 
below 50, but in one particular animal, the count 
value often exceeded 100 epg after Day +261 and 
on one occasion even reached 326 epg.
In group 2, treated monthly from Day –28, no eggs 
were ever found throughout the study.
In group 3, treated weekly from Day +170, epg val-
ues were initially similar to those found in group 
1, but, as the study progressed, the values became 
lower and egg findings more sporadic. On Days 
+170/+177, eggs were found in the faeces of six of 
the eight dogs. From Day +208 eggs were found 
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in the faeces of only two dogs, from Day +233 in 
the faeces of only one dog and from Day +254 eggs 
were no longer found in the faeces of any of the 
dogs (Fig. 3). The percentage reduction in egg out-
put when compared to the control group, although 
variable, was initially over 85 % and progressed 
to over 90 % from Day +208 and 100 % from Day 
+254 onwards.
Lesions in the aorta recorded at necropsy
In the untreated control group 1, the number of 
lesions on the inside of the thoracic aorta varied 
in number from 5 to 17 between individual dogs 
(median 11.5; geometric mean 10.7). Typical 
nodules were mostly absent and the lesions remain-
ing were made up of puckered areas and small to 
large aneurisms. No S. lupi worms remained in the 
wall of the aorta. The scores awarded as a means of 
quantifying the damage to the aorta are depicted 
in Table 4 and varied from 3.5 to 5 (median 4.25; 
geometric mean 4.23).
In group 2, treated from Day –28, no sign of any 
lesions could be found in the thoracic aorta of seven 
of the eight dogs, which were awarded damage 
scores of 1. In one dog, two small puckered areas 
were seen around an arterial branch, so small that 
microscopic examination was necessary, which still 































































Fig. 3  Faecal Spirocerca lupi egg counts were conducted from approximately 6 months (study day +170) after
experimental infection of the dogs. Egg counts are expressed as eggs per gram of faeces (epg) and the graph 
shows mean epg values, determined approximately weekly, for dogs in groups 1 and 3. No S. lupi eggs were 
present in the faeces of dogs in group 1
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have been caused by S. lupi larvae (median 0.0; geo-
metric mean 0.1). The cause of the lesions remained 
inconclusive but a damage score of 1.5 was awarded 
(median 1.0; geometric mean 1.06).
In group 3, treated from Day +170, the damage to 
the aorta closely resembled that in group 1. The 
number of lesions varied from 6–16 (median 10.0; 
geometric mean 10.4), and damage scores varied 
from 3–6 (median 4.5; geometric mean 4.43).
It is evident that groups 1 and 3 did not differ sig-
nificantly with regard to both parameters meas-
ured and the damage to the aorta was similar for 
the two groups. Damage to the aorta was signifi-
cantly less in group 2 than in either of the other 
two groups (Table 4).
Figures 4a to 4c show some examples of the thorac-
ic aorta of individual dogs where either no damage 
or various degrees of damage occurred, as well as 
the scores that were awarded.
Lesions in the oesophagus recorded at 
necropsy (Table 5)
In the untreated control group 1, nodules were 
present in the oesophagus of all dogs, varying in 
number from 1 to 3 (median 2.5; geometric mean 
2.1). The nodules were mostly large and all of them 
contained adult S. lupi worms.
In group 2, treated from Day –28, no sign of any 
nodules could be found in the oesophagus of any 
of the dogs.
In group 3, treated from Day +170, nodules were 
found in the oesophagus of three dogs (median 0.0; 
geometric mean 0.4) In two of the dogs, with only 
one nodule each, the nodules were of average size 
and contained one or two worms. The other dog 
had two very small nodules in the oesophagus and 
these contained no worms.
The average nodule size was also compared 
between the three groups by the use of an ANOVA. 
It is evident that the oesophageal nodules found in 
group 3 were significantly smaller than those in the 
control group. Figures 5a and 5b show examples 
Table 4 Comparative aortic damage at necropsy
Group Treatment No of lesons (GM) Damage score (GM)
1 Untreated control group 10.7 4.23
2 Monthly prevention from Day –28 0.1a 1.06c
3 Weekly therapy from Day 170 10.4b 4.43d
a p value for difference to group 1 and 3: 0.0003 b p value for difference to group 1: 0.2077
c p value for difference to group 1 and 3: 0.0003 d p value for difference to group 1: 0.4160
Table 5 Comparative lesions in the oesophagus at necropsy
Group Treatment No of nodules (GM) Size of nodules
1 Untreated control group 2.1 Mostly large
2 Monthly prevention from Day –28 0a 0c
3 Weekly therapy from Day 170 0.4b Averaged
a p value for difference to group 1: 0.0002; p value for difference to group 3: 0.038
b p value for difference to group 1: 0.002
c p value for difference to group 1: < 0.0001; p value for difference to group 3: 0.036
d p value for difference to group 1: < 0.0001
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of oesophageal nodules seen from both the outside 
and the inside of the oesophagus from a dog in the 
untreated control group.
Worm numbers and calculation of effi cacy
The total worm numbers recovered from oesopha-
geal nodules of dogs in the three study groups at 
necropsy are shown in Table 6.
In the untreated control group 1, S. lupi worms 
were recovered from oesophageal nodules in all 
dogs. Total numbers of S. lupi recovered per dog 
varied from 10 to 31, geometric mean 16.9. In 
total 144 worms were recovered from the control 
dogs and this represented 45 % of the 320 S. lupi 
L3 larvae with which the eight dogs were infected, 
closely corresponding to the 47 % recorded by Bai-
ley (1972). The dogs in the control group were thus 
adequately infected with S. lupi as a result of the 
experimental infections. Vomiting, which followed 
after dosing with the L3 larvae, evidently had 
little effect on the success of establishment of the 
parasites.
In group 2, treated from Day –28, no S. lupi worms 
occurred in the oesophagus.
In group 3, treated from Day +170, S. lupi worms 
were found only in the two dogs with the larger 
nodules, which harboured one and two worms, 
respectively (geometric mean 0.3).
Effi cacy against encapsulation of immature 
S. lupi worms
Percentage efficacy, as a measure of a treatment 
effect to prevent encapsulation of the immature 
stages of S. lupi, was the primary endpoint for 
group 2. In this group, no S. lupi worms or any 
Fig. 4a  Aorta (from a dog in group 2 treated monthly 
from Day –28) with no lesions awarded a
damage score 1
Fig. 4b  Aorta (from a dog in group 3 treated weekly 
from Day +170) awarded a damage score 5. 
Many lesions, some of which are indicated by 
arrows, can be seen in the wall of the aorta
Fig. 4c  Aorta (from a dog in group 3 treated weekly 
from Day +170) awarded a damage score 6. 
The wall of the aorta shows extensive damage 




lesions caused by S. lupi during any stage of the 
life cycle were ever found in any of the dogs at 
necropsy. The treatment regimen was thus 100 % 
effective in preventing encapsulation of S. lupi fol-
lowing experimental infection (Table 6).
Efficacy against encapsulated adult 
S. lupi worms
Percentage efficacy, as a measure of a treat-
ment effect against encapsulated adults, was the 
primary endpoint for group 3. L3 S. lupi larvae, 
introduced during the experimental infections, 
successfully established themselves in the tho-
racic aorta of the dogs in group 3, subsequently 
migrating to and forming nodules in the oesopha-
gus of all but one of the dogs, as determined during 
endoscopic examinations. S. lupi eggs, albeit few, 
were shed in the faeces of six of the eight dogs in 
group 3 between Day +170 and +245. The above 
indicates that the infections were well established 
in the group 3 dogs by the time of the first IVP 
treatment on Day +170.
The geometric mean number of S. lupi recovered at 
necropsy from dogs in the untreated control group 
1 was 16.9, compared to 0.3 in group 3. Efficacy of 
the treatment regimen was 98.5 % (Table 6) against 
encapsulated adults in group 3 (97.9 % based on 
arithmetic means).
Table 6  Total number of Spirocerca lupi worms recovered from oesophageal nodules of dogs in groups 1–3 during necropsy
Group Total S. lupi worms GM
Percentage efficacy
Preventive Therapeutic
1 144 16.39 Not applicable
2 0 0.0 100.0 ­­­­
3 3 0.3 ­­­­ 98.5
Fig. 5a  Outer view of oesophageal nodules in a dog 
from group 1. Two large nodules, indicated by 
arrows, can be seen in the proximal part of the 
oesophagus; part of the stomach is visible on 
the far left. See also Fig. 5b
Fig. 5b  The oesophagus shown in Fig. 5a opened so 
that nodules are viewed from the lumen side. 
Orifices connect the nodules to the oesophagus 
and these enable female worms to lay their 
eggs in the oesophageal lumen. One adult 
worm (arrow 1) can be seen protruding from an 
orifice and a second adult (arrow 2) lie free on 




Prevention of this disease by control of intermedi-
ate or paratenic host is impractical and difficult 
to achieve, since the spectrum of intermediate and 
paratenic hosts is so diverse (Bailey 1972; Bow-
man 2009; Taylor et al. 2007), a situation similar to 
other severe parasitic diseases such as angiostron-
gylosis, which depends on a variety of molluscan 
intermediate hosts and vertebrate paratenic hosts 
(Bolt et al 1993, Ferdushy and Hasan 2010). There-
fore control of Spirocerca lupi in the final host by 
medical prevention or therapy seems to be the only 
viable option.
Most studies in which macrocyclic lactones were 
tested for efficacy against S. lupi focused on thera-
peutic efficacy (Berry 2000; Lavy et al. 2002; Kelly 
et al. 2008), and although some treatment regi-
mens have indicated promising preventative effi-
cacy (Lavy et al. 2003; Kok et al. 2010; Le Sueur 
et al. 2010), this issue remains largely unresolved. 
The present study was designed to evaluate both 
preventative and therapeutic efficacy in experi-
mentally infected animals. Assessment included 
not only oesophagoscopy but also faecal egg counts 
and quantification of pathological changes and 
worm numbers during necropsy.
In spite of the fact that dogs invariably vomited 
shortly after infection with the S. lupi L3 larvae, 
the establishment of the parasites was not nega-
tively affected. The dogs in the negative control 
group were adequately infected with S. lupi, as con-
cluded from the extensive damage caused by 
the worms in the wall of the thoracic aorta, the 
nodules formed in the oesophagus and the large 
numbers of worms recovered from the oesophageal 
nodules. The percentage establishment was closely 
similar to that reported by Bailey (1972), namely 
45 % asopposed to 47 %, and was slightly higher 
than that reported by Kok et al. (2011). The adequa-
cy of infection in the control group enabled a valid 
comparison of treated groups to the control group.
The use of oesophagoscopy to detect oesophageal 
nodules associated with S. lupi infections is a 
standard diagnostic procedure (Mazaki-Tovi et al. 
2002) and has been used often in studies to deter-
mine the efficacy of therapeutic procedures in the 
treatment of progressed spirocercosis (Lavy et al. 
2003; Kelly et al. 2008; Le Sueur et al. 2010; Lobetti 
2000).
In the present study, endoscopy proved to be a 
valuable tool to determine whether or not oesoph-
ageal spirocercosis had already developed in dogs 
six months after the experimental introduction of 
L3 larvae. The procedure confirmed that all dogs in 
the untreated control group and all but one of the 
dogs in group 3, until then untreated, had oesopha-
geal nodules. This confirmation allowed investiga-
tors to go ahead with the therapeutic treatments 
of the animals in group 3. At the same time, the 
absence of any oesophageal lesions in the dogs in 
group 2 already indicated the preventative efficacy 
of the monthly treatments that had started before 
the first experimental infections.
In the follow-up endoscopic examinations of ani-
mals in group 3, nodules were still recorded as pre-
sent in seven of the eight dogs 2–3 weeks before 
necropsy. However, at necropsy nodules were 
found in only three of the dogs. The authors suggest 
that because of the elasticity of the oesophagus, 
its mucosa is strongly folded; these folds tend to 
form small ridges which could have been mistaken 
for nodules that were not yet completely resolved. 
Researchers tended to record any ridges/swellings 
as nodules rather than missing any actual nod-
ules, and were therefore likely to overestimate the 
number of nodules during such endoscopic exami-
nations. On re-examination of video clips taken in 
this study during examinations, such ridges could 
mostly be identified as ridges and not as nodules.
Faecal egg counts proved to be supportive of the 
early endoscopic confirmation of patent infections 
in dogs belonging to groups 1 and 3, and the appar-
ent absence of infections in dogs of group 2. Thera-
peutic efficacy of the treatment of dogs in group 
3 was also indicated early after the start of treat-
ment by the egg numbers that never increased to 
meaningful numbers (compared to those of the 
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control group) and gradually disappeared from 
the faeces. Lavy et al. (2002, 2003) reported on the 
value of egg counts in the assessment of therapeu-
tic efficacy but le Sueur et al. (2010) did not obtain 
any useful results from faecal examinations.
As a first objective of the present study, one group of 
dogs was treated 30 days before the first experimen-
tal infection and monthly thereafter to determine 
whether or not the treatment would effectively 
prevent the establishment of S. lupi larvae in the 
thoracic aorta as well as the associated damage to 
the wall of the aorta. It was shown that for group 
2 the efficacy of prevention was 100 %, based on the 
results of endoscopic visualisation, faecal examina-
tions and most importantly, necropsy examination 
of the thoracic aorta. The latter is the only assess-
ment that can unequivocally determine whether or 
not the aorta was damaged. Kok et al. (2010) have 
shown that even in animals that responded posi-
tively to treatment for the prevention of oesopha-
geal spirocercosis, damage to the thoracic aorta still 
occurred and could only be quantified during post-
mortem examination of the aorta. Kirberger et al. 
(2013) have shown that computed tomographic and 
radiographic procedures can be used to detect aortic 
lesions but these are likely to be of value mainly 
when gross lesions are present.
These results obtained during an experimental 
infection confirm those of Le Sueur et al. (2010) 
who reported on the high efficacy of an imidaclo-
prid 10 %/moxidectin 2.5 % spot-on to prevent infec-
tion with S. lupi in a large population of young dogs 
naturally exposed to S. lupi on Réunion Island.
As a second objective of the study the dogs in group 
3 were treated for the first time at about 6 months 
post infection, when it had been confirmed by endo-
scopic examination that seven out of the eight dogs 
already had oesophageal spirocercosis. The dogs 
were then treated weekly thereafter to determine 
whether or not the treatment would effectively 
reduce the number of S. lupi adults inhabiting 
the oesophageal nodules and at the same time 
resolve the nodules. Nineteen weekly treatments 
were given over a period of 128 days and necropsy 
followed 14 days later. Only small nodules remained 
in the oesophagus of three of the dogs and only 
three S. lupi worms were recovered from two of 
the dogs (efficacy of treatment calculated as 98.5 % 
against the adult worms). As was expected, dam-
age to the aorta of dogs in group 3 did not differ 
from that seen in the untreated control dogs. Even 
when dogs recover from oesophageal spirocerco-
sis, they remain at risk because of the irreversible 
damage to the aorta. Sudden death may thus still 
occur in case of a ruptured aorta. This underlines 
the importance of prevention of infection, in order 
to avoid extensive damage of the aorta caused 
during the development of the parasite.
A number of studies have been conducted with the 
aim to determine therapeutic efficacy of macro - 
cyclic lactones, notably doramectin and milbemycin 
oxime. In all of these studies, with either naturally 
or experimentally infected clinical cases, assessment 
was done with endoscopic examination of nodules 
to determine successful resolution. Resolution of 
nodules, not necessarily complete, occurred after 
42–84 days (Berry 2000), 35–544 days (Lavy et al. 
2002), 60–180 days (Mylonakis et al. 2004) and 
95–186 days (Kelly et al. 2008). Doramectin was 
mostly injected subcutaneously at 200 to 400 µg/kg at 
14-day to monthly intervals for up to 20 treatments. 
However, Mylonakis et al. (2004) also gave daily oral 
doses of doramectin to two dogs, and Lobetti (2012) 
followed this procedure in a study with 20 naturally 
infected dogs dosed daily with 500 µg/kg oral dora-
mectin and reported the resolution of oesophageal 
nodules after 42–126 days. Kelly et al. (2008) dosed 
dogs with oral milbemycin oxime.
In the present study, resolution of oesophagel nod-
ules was almost complete after 19 weekly spot-on 
treat ments with imidacloprid 10 %/moxidectin 2.5 % 
(Advocate®, Advantage Multi®, Bayer) over a 
period of 128 days. Only three live worms were 
recovered from the treated group as opposed to 
144 from the control group (efficacy 98.5 %).
The product used in this study contains a combina-
tion of imidacloprid and moxidectin in concentra-
tions of 10 % and 2.5 %, respectively. Imidacloprid 
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is a topically applied, non-systemic insecticide 
belonging to the chloronicotinyl class of compounds. 
It was first discovered in 1984 and introduced onto 
the market in 1991, its main function in veterinary 
medicine being the control of fleas on dogs and cats 
(Mencke and Jeschke 2002).
Moxidectin is a pentacyclic lactone endectocide of the 
milbemycin class of compounds, chemically derived 
from the macrocylic lactone nemadectin, first iso-
lated in 1983 as a fermentation product of the bac-
terium Streptomyces cyaneogriseus (Prichard et al. 
2012; Rock et al. 2003). Moxidectin has an extremely 
high lipophilicity, approximately 100 times higher 
than that of ivermectin, and this contributes to its 
very high volume of distribution (Hennessy and 
Alvinerie 2003). These factors, combined with an 
elimination half-life of 19 days in the dog (Vana-
palli et al. 2002), give moxidectin an extended post-
administration residual action in the body.
Macrocyclic lactones exert their anthelmintic effect 
by binding to glutamate-gated chloride channels, 
which are expressed on nematode neurones and 
pharyngeal muscle cells. The net effect of this bind-
ing is an irreversible opening of these channels, 
leading to prolonged hyper- or depolarisation of 
the nerve cell, preventing further functioning and 
ultimately leading to paralysis (Wolstenholme and 
Rogers 2005).
When looking at the life cycle of S. lupi, it stands 
to reason that the ideal product for preventing and 
treating infections with this parasite should pre-
sent a high level of efficacy against immature and 
mature stages of this nematode, a high volume of 
distribution and an extended period of action in 
order to be effective. Other important product 
attributes would include safety in target species 
as well as ease of administration.
It is evident that different macrocyclic lactones 
are promising in the prevention and therapeutic 
treatment of spirocercosis. Disadvantages are that 
products are often not licensed and may require 
high doses or administration by a veterinarian. 
In this regard, Kelly et al. (2008) emphasised the 
practical advantages of oral doses of milbemycin 
oxime. The convenience of using the tested formu-
lation as a spot-on formulation in either weekly 
or monthly treatments exceeds that of any other 
product hitherto used. Furthermore, the efficacy of 
imidacloprid 10 %/moxidectin 2.5 % against migrat-
ing and encapsulated phases of S. lupi was proven 
conclusively in the present study.
At no time during the study any adverse reaction 
to the topically applied product was noted. A total 
of 19 treatments were applied weekly to the treat-
ment group 3 with no manifestation of any undesir-
able side effects. It must be stated that none of the 
dogs used in this study belonged to the collie or any 
related breeds which are known for their predispo-
sition to defects of the MDR I gene and subsequent 
susceptibility to neurological macrocyclic lactone 
toxicity (Mealey 2004; Mealey et al. 2001).
In July 2012, imidacloprid 10 %/moxidectin 2.5 % 
(Advocate®, Bayer) was officially licensed in South 
Africa for the prevention and treatment of Spirocer-
ca lupi infections based on the results of this study, 
and to the authors’ best knowledge became the first 
product in the world to receive this indication.
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